This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Squibb Prices $1.5 Billion Of Senior Notes

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell $1.5 billion of senior unsecured notes: $500,000,000 million in aggregate principal amount of 1.750% notes due 2019, $500,000,000 million in aggregate principal amount of 3.250% notes due 2023 and $500,000,000 million in aggregate principal amount of 4.500% notes due 2044, in an underwritten public offering.

Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BNP Paribas Securities Corp., Credit Suisse Securities (USA) LLC and RBS Securities Inc. are acting as joint book-running managers of the underwriters.

Bristol-Myers Squibb intends to use the net proceeds from the offering for general corporate purposes, including the repayment of all or a portion of its commercial paper borrowings. The offering is expected to close on October 31, 2013, subject to customary closing conditions.

When available, the final prospectus supplement and accompanying prospectus relating to the offering of the notes may be obtained by contacting one of the following joint book-running managers:

  • Deutsche Bank Securities Inc., at: 800-503-4611
  • J.P. Morgan Securities LLC, at: 212-834-4533
  • Barclays Capital Inc., at: 888-603-5847
  • BNP Paribas Securities Corp., at: 800-854-5674
  • Credit Suisse Securities (USA) LLC, at: 800-221-1037
  • RBS Securities Inc., at: 866-884-2071

The final prospectus supplement and accompanying prospectus, when available, may also be accessed through the SEC’s website at www.sec.gov.

These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs